Skip to main content

A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF-07284890 (ARRY-461) IN PARTICIPANTS WITH BRAF V600-MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Pfizer, Inc.

Start Date

November 19, 2020

End Date

December 9, 2025
 

Administered By

Duke Cancer Institute

Awarded By

Pfizer, Inc.

Start Date

November 19, 2020

End Date

December 9, 2025